Show
Sort by
-
Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
-
- Journal Article
- A1
- open access
Safety and outcomes of amikacin liposome inhalation suspension for Mycobacterium abscessus pulmonary disease : a NTM-NET
-
- Journal Article
- A1
- open access
Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge
-
Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection
-
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies
-
Defining polysaccharide antibody deficiency : measurement of anti-pneumococcal antibodies and anti-Salmonella typhi antibodies in a cohort of patients with recurrent infections
-
Clinical relevance of pulmonary non-tuberculous mycobacterial isolates in three reference centres in Belgium : a multicentre retrospective analysis
-
Adherence to NTM treatment guidelines in three reference centers in Belgium
-
- Journal Article
- A1
- open access
Clinical relevance of pulmonary non-tuberculous mycobacterial isolates in three reference centres in Belgium : a multicentre retrospective analysis